Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27229424 | 1.00 | PTPN6 (0.36) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL26674693 | 0.83 | IDO1 (0.43) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL31692056 | 0.83 | IDO1 (0.43) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL21379148 | 0.83 | METAP2 (0.33) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL30641268 | 0.83 | NOS1 (0.34) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL25218289 | 0.83 | NOS1 (0.34) | METAP2IDO1TDO2NOS1AXL | |
| SCHEMBL30641272 | 0.83 | METAP2 (0.33) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL15265828 | 0.78 | NOS1 (0.36) | PTPN6METAP2IDO1TDO2NOS1 | |
| SCHEMBL26440179 | 0.78 | KDM4E (0.37) | PTPN6METAP2IDO1TDO2 | |
| SCHEMBL30641196 | 0.77 | MAPT (0.42) | IDO1TDO2NOS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| CN-120077034-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | PTPN6 1606/4885METAP2 558/4885IDO1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.